
|Videos|June 30, 2017
Long-Term Data Confirm TH Benefit in Early HER2-Positive Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
This video highlights 7-year follow-up data from the APT trial, which studied adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Advertisement
In this video, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses 7-year follow-up data of the APT trial, which studied adjuvant paclitaxel/trastuzumab (TH) in early-stage patients with node-negative, HER2-positive breast cancer.
Tolaney presented the study results (
Advertisement
Related Content
Advertisement

ByAdam M. Brufsky, MD, PhD,François-Clément Bidard,Erica L. Mayer, MD, MPH,Yeon Hee Park,Wolfgang Janni,Cynthia X. Ma, MD, PhD,Massimo Cristofanilli, MD,Giampaolo Bianchini,Kevin Kalinsky, MD, MS,Hiroji Iwata,Stephen Chia,Peter A. Fasching,Zbigniew Nowecki,Javier Pascual,Einav Nili Gal-Yam,Wei-Pang Chung,Seock-Ah Im,Alberto Zambelli,Florence Dalenc,Mafalda Oliveira,Steven Fox,Manuel Selvi Miralles,Christopher Morrow,Cynthia Huang Bartlett,Nicholas C. Turner, MD



109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR
ByDiana I. Lüftner,Rupert Bartsch,Urs Breitenstein,Christian Jackisch,Volkmar Mueller,Marcus Schmidt,Marija Balic,Gabriel Rinnerthaler,Khalil Zaman,Michael Schwitter,Denise Wrobel,Dagmar Guth,Matthias Zaiss,Jürgen Terhaag,Lidia Perlova-Griff,Rachel Wuerstlein,Timo Schinköthe,Corinne Vannier,Nadia Harbeck, MD, PhD

110 Randomized Phase II Trial Evaluating Three Anti-diarrheal Prophylaxis Strategies in Patients (pts) with HER2+/HR+ Early Breast Cancer (EBC) Treated with Extended Adjuvant Neratinib (Dianer Geicam/2018-06)
ByJ. Gil-Gil,M. Ruíz-Borrego,E. Carrasco,Y. Izarzugaza,C. Martínez-Vila,E. Galve,B. López-Barajas,E. Adrover,T. Silovski,M. Valero-Arbizu,Á. Guerrero-Zotano,S. González-Santiago,M. Echarri,A. Cano-Jiménez,A. Vethencourt-Casado,M. De Laurentis,C. Bueno-Muiño,B. Adamo,R. Andrés,C. Villanueva,F. Rojo,M. Casas,P. Wilson,J. Suissa,V. Adams,M. Martin


















